iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
7.42
+0.20 (2.77%)
At close: Dec 20, 2024, 4:00 PM
7.45
+0.03 (0.41%)
After-hours: Dec 20, 2024, 7:29 PM EST
iTeos Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for iTeos Therapeutics stock have an average target of 21.33, with a low estimate of 19 and a high estimate of 24. The average target predicts an increase of 187.47% from the current stock price of 7.42.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ITOS stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $31 → $19 | Buy | Maintains | $31 → $19 | +156.06% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +183.02% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +519.95% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +519.95% | Sep 16, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $31 | Buy | Initiates | $31 | +317.79% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
46.75M
from 12.60M
Increased by 271.18%
Revenue Next Year
6.83M
from 46.75M
Decreased by -85.39%
EPS This Year
-3.41
from -3.15
EPS Next Year
-4.31
from -3.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 105.0M | 38.9M | 35.4M | |||
| Avg | 46.8M | 6.8M | 15.1M | |||
| Low | 34.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 733.7% | -16.9% | 418.9% | |||
| Avg | 271.2% | -85.4% | 121.7% | |||
| Low | 172.3% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.22 | -3.29 | -3.53 | |||
| Avg | -3.41 | -4.31 | -4.29 | |||
| Low | -3.66 | -6.68 | -5.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.